ECSP16061208A - Quinazolin-thf-aminas como inhibidores de pde1 - Google Patents

Quinazolin-thf-aminas como inhibidores de pde1

Info

Publication number
ECSP16061208A
ECSP16061208A ECIEPI201661208A ECPI201661208A ECSP16061208A EC SP16061208 A ECSP16061208 A EC SP16061208A EC IEPI201661208 A ECIEPI201661208 A EC IEPI201661208A EC PI201661208 A ECPI201661208 A EC PI201661208A EC SP16061208 A ECSP16061208 A EC SP16061208A
Authority
EC
Ecuador
Prior art keywords
quinazolin
thf
amines
pde1 inhibitors
pde1
Prior art date
Application number
ECIEPI201661208A
Other languages
English (en)
Inventor
Morten Langgard
Jan Kehler
Lars Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of ECSP16061208A publication Critical patent/ECSP16061208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona quinazolin-THF-aminas como inhibidores de PDE1 y su uso como un medicamento, en particular para el tratamiento de trastornos neurodegenerativos y trastornos psiquiátricos.
ECIEPI201661208A 2013-12-19 2016-07-18 Quinazolin-thf-aminas como inhibidores de pde1 ECSP16061208A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201300707 2013-12-19
DKPA201400249 2014-05-06

Publications (1)

Publication Number Publication Date
ECSP16061208A true ECSP16061208A (es) 2017-08-31

Family

ID=52350066

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201661208A ECSP16061208A (es) 2013-12-19 2016-07-18 Quinazolin-thf-aminas como inhibidores de pde1

Country Status (26)

Country Link
US (3) US20150175584A1 (es)
EP (1) EP3083607B1 (es)
JP (1) JP6419832B2 (es)
KR (1) KR20160098269A (es)
CN (1) CN105829300B (es)
AP (1) AP2016009293A0 (es)
AU (1) AU2014368601B2 (es)
BR (1) BR112016013946A8 (es)
CA (1) CA2933299A1 (es)
CL (1) CL2016001488A1 (es)
CR (1) CR20160282A (es)
DO (1) DOP2016000152A (es)
EA (1) EA201691108A1 (es)
EC (1) ECSP16061208A (es)
ES (1) ES2728079T3 (es)
GE (1) GEP201706764B (es)
IL (1) IL246230A0 (es)
MX (1) MX2016007945A (es)
PE (1) PE20160855A1 (es)
PH (1) PH12016501173A1 (es)
RU (1) RU2016125315A (es)
SG (1) SG11201604936TA (es)
SV (1) SV2016005220A (es)
TN (1) TN2016000239A1 (es)
TW (1) TW201609713A (es)
WO (1) WO2015091805A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
EA032579B1 (ru) * 2014-04-04 2019-06-28 Х. Лундбекк А/С Галогенированные хиназолин-тгф-амины в качестве ингибиторов pde1
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20220184240A1 (en) 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575916B1 (en) * 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
CN1802177A (zh) * 2003-04-01 2006-07-12 应用研究系统Ars股份公司 用于不育症中的磷酸二酯酶抑制剂
CA2565037A1 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
EP1940819A1 (en) * 2005-08-16 2008-07-09 Memory Pharmaceuticals Corporation Phosphodiesterase 10 inhibitors
WO2007096743A1 (en) * 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
EP2279009A4 (en) * 2008-05-05 2011-09-21 Univ Rochester METHOD AND COMPOSITIONS FOR TREATING OR PREVENTING PATHOLOGICAL CARDIAL REMODELING AND HEART FAILURE
EP2434895A4 (en) * 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP2480537A1 (en) * 2009-09-24 2012-08-01 Basf Se Aminoquinazoline compounds for combating invertebrate pests
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺

Also Published As

Publication number Publication date
TN2016000239A1 (en) 2017-10-06
US9701665B2 (en) 2017-07-11
EP3083607B1 (en) 2019-04-24
US20170267664A1 (en) 2017-09-21
AP2016009293A0 (en) 2016-06-30
BR112016013946A8 (pt) 2018-01-30
BR112016013946A2 (pt) 2017-08-08
JP6419832B2 (ja) 2018-11-07
PH12016501173A1 (en) 2016-08-15
AU2014368601A1 (en) 2016-06-30
CN105829300B (zh) 2019-03-15
US10030007B2 (en) 2018-07-24
CN105829300A (zh) 2016-08-03
EP3083607A1 (en) 2016-10-26
RU2016125315A (ru) 2018-01-24
EA201691108A1 (ru) 2016-09-30
US20150175584A1 (en) 2015-06-25
GEP201706764B (en) 2017-10-25
TW201609713A (zh) 2016-03-16
PE20160855A1 (es) 2016-09-23
CL2016001488A1 (es) 2016-12-09
DOP2016000152A (es) 2016-09-30
US20160318910A1 (en) 2016-11-03
CR20160282A (es) 2016-09-06
SG11201604936TA (en) 2016-07-28
AU2014368601B2 (en) 2018-07-05
SV2016005220A (es) 2016-11-30
CA2933299A1 (en) 2015-06-25
KR20160098269A (ko) 2016-08-18
ES2728079T3 (es) 2019-10-22
WO2015091805A1 (en) 2015-06-25
IL246230A0 (en) 2016-08-02
MX2016007945A (es) 2016-10-12
JP2017500339A (ja) 2017-01-05

Similar Documents

Publication Publication Date Title
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
MX2018015734A (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde1.
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..
MX2015013378A (es) Uso de sedoheptulosa para la prevencion y tratamiento de inflamacion.